Tercer Taller Virtual Nacional de Generalización

Impacto material de técnica de inmunohistoquímica en pacientes con cáncer de mama en matanzas. 2016-2020
Luís Enrique Curbelo Gutiérres

Última modificación: 2023-03-18

Resumen


El año de mayor diagnóstico de cáncer de mama en Matanzas fue 2020 y en todos los años de estudio el grupo predominante fue el de inmunofenotipo desconocido. Según el resultado de inmunohistoquímica 1 de cada 5 pacientes fue Luminal A con rango de edad más frecuente entre los 60 y 79 años. La cantidad de pacientes que obtuvo resultado de inmunohistoquímica en tiempo menor a 1 mes no fue significativa. La técnica de inmunohistoquímica representa un impacto material negativo en el Centro Oncológico Provincial de Matanzas y finalmente quedó demostrado el beneficio en la implementación de la técnica de inmunohistoquímica en la provincia de Matanzas.

Descargar fichero


Citas


REFERENCIAS BIBLIOGRÁFICAS

  1. Hu K, Ding P, Wu Y, et. al. Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases. BMJ Open. 2019 oct 7;9(10): e028461. doi: 10.1136/bmjopen-2018-028461. PMID: 31594871; PMCID: PMC6797270
  2. Iñiguez Rojas L. Aproximación a la evolución de los cambios en los servicios de salud en Cuba. Rev Cubana Salud Pública [Internet]. 2012 Mar [citado 19 octubre 2020]; 38(1): 109-25. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S086434662012000100011&lng=es
  3. Lineamientos de la Política Económica y Social del Partido y la Revolución (Internet). La Habana: PCC; 2011 (citado 19 octubre 2020. Disponible en: http://.cubadebate.cu/wp-content/uploads/2011/05/folleto-lineamientos-vicong.pdf
  4. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario estadístico [Internet]. La Habana: MINSAP; 2017 [citado 19 octubre 202]. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf
  5. Periódico Juventud Rebelde. Lunes 06 de junio de 2020.  ISSN 1563-8340.
  6. García Fariñas A, Gálvez González AM, García Rodríguez JF. Aspectos metodológicos críticos en las evaluaciones económicas de salud en el contexto cubano. Rev Cubana Salud Pública [Internet]. 2010 [citado 19 octubre 2020]; 36(3):233-5. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S086434662010000300007&lng=es
  7. Drummond M. Twenty years of using economic evaluations for reimbursement decisions. What have we achieved? York: Univerisity of York, Centre for Health Economics; 2012.
  8. Ríos Hidalgo, N. Patología General. ECIMED 2014: 19. ISBN 978-959-212-884-2.
  9. Surenkok S, Tahberer E, Cinkaya A, Kodaz H, Deger A. Metaplastic breast cancer: A case report. J Pak Med Assoc. 2018 Mar;68(3):466-468. PMID: 29540888.

10. Lluch A, Eroles P, Bosch A, Pérez-Fidalgo JA. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. PMID: 22178455.

11. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28. PMID: 29593010.

12. MINSAP. Dirección de registros médicos y estadísticas de salud. 2019. Anuario estadístico de salud. 2020; ISSN: versión electrónica 1561-4433.

13. Ministerio de Salud Pública. Anuario Estadístico de Salud 2018. La Habana. Cuba [Internet]. 2019 (citado 19 octubre 2020); Versión electrónica ISSN: 1561-4433. Disponible en: https://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf

14. Lee K, Kruper L, Dieli-Conwright CM, Mortimer JE. The Impact of Obesity on Breast Cancer Diagnosis and Treatment. Curr Oncol Rep. 2019 Mar 27;21(5):41. doi: 10.1007/s11912-019-0787-1. PMID: 30919143; PMCID: PMC6437123.

15. Provenzano E, Ulaner GA, Chin SF. Molecular Classification of Breast Cancer. PET Clin. 2018 Jul;13(3):325-338. doi: 10.1016/j.cpet.2018.02.004. Epub 2018 May 7. PMID: 30100073.

16. Marrazzo E, Frusone F, Milana F.et al. Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020 Feb; 49:87-92. doi: 10.1016/j.breast.2019.11.002. Epub 2019 Nov 11. PMID: 31783314; PMCID: PMC7375663.

17. Treitl D, Radkani P, Rizer M, El Hussein S, Paramo JC, Mesko TW. Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature. Breast Cancer. 2018 Jan; 25(1):28-33. doi: 10.1007/s12282-017-0780-1. Epub 2017 May 2. PMID: 28466440.

18. Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, et. al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology. 2019 Aug; 75(2):213-224. doi: 10.1111/his.13879. Epub 2019 Jul 10. PMID: 31012486; PMCID: PMC6646069.

19. Miricescu D, Totan A, Stanescu-Spinu II, et. al. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020 Dec 26;22(1):173. doi: 10.3390/ijms22010173. PMID: 33375317; PMCID: PMC7796017.

20. Sherwell-Cabello S, Maffuz-Aziz A, Hernández-Hernández B,et. al. Carcinoma metaplásico de mama y repercusión de la expresión de p63 y citoqueratina 5/6: experiencia de 40 pacientes [Metaplastic carcinoma of the breast and the impact of the p63 and cytokeratin 5/6: experience of 40 patients]. Ginecol Obstet Mex. 2016 Mar;84(3):127-35. Spanish. PMID: 27424438.

21. Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020 Mar;112(1):25-41. doi: 10.32074/1591-951X-1-20. PMID: 32202537; PMCID: PMC8138497.

22. Limaïem F, Bouraoui S. Carcinome micropapillaire invasif: une tumeur mammaire rare et aggressive [Invasive micropapillary carcinoma: a rare and aggressive breast cancer]. Pan Afr Med J. 2021 Sep 9;40:29. French. doi: 10.11604/pamj.2021.40.29.31348. PMID: 34733397; PMCID: PMC8531961.

23. Zhao Y, Gong X, Li N, Zhu B, Yu D, Jin X. Fibromatosis-like metaplastic carcinoma of breast: a challenge for clinicopathologic diagnosis. Int J Clin ExpPathol. 2018 Jul 1; 11(7):3691-3696. PMID: 31949751; PMCID: PMC6962846.

24. Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019 Sep;79:101888. doi: 10.1016/j.ctrv.2019.08.004. Epub 2019 Aug 13. PMID: 31491663.

25. Ilhan B, Emiroğlu S, Türkay R, Ilhan R. The role of histopathologic testing on apocrine carcinoma of the breast. CurrProbl Cancer. 2020 Apr; 44(2):100501. doi: 10.1016/j.currproblcancer.2019.100501. Epub 2019 Sep 7. PMID: 31521370.

26. Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol. 2003 Jul; 56(7):497-506. doi: 10.1136/jcp.56.7.497. Erratum in: J Clin Pathol. 2003 Oct; 56(10):804. PMID: 12835294; PMCID: PMC1769991.

27. Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, Massocco A, et al. Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. Oncologist. 2016 Jan; 21(1):28-32. doi: 10.1634/theoncologist.2015-0309. Epub 2015 Dec 9. PMID: 26659223; PMCID: PMC4709213.

28. Budny A, Starosławska E, Budny B, Wójcik R,et. al. Epidemiologia oraz diagnostyka raka piersi [Epidemiology and diagnosis of breast cancer]. Pol Merkur Lekarski. 2019 May 27;46(275):195-204. Polish. PMID: 31152530.

29. Ortiz Hidalgo C. Breve nota sobre la historia de la inmunohistoquímica. Historia y filosofía. Patología. 2018; 56(2):46-59

30. Wallden B, Storhoff J, Nielsen T, et. al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6. PMID: 26297356; PMCID: PMC4546262

31. Jaramillo JA. Clasificación molecular del cáncer de mama por técnica de inmunohistoquímica en Magdalena, Colombia. Revista colombiana de patología. 2019 1(7) 23. ISSN:2665-4008

32. Yeo SK, Guan JL. Breast Cancer: Multiple Subtypes within a Tumor? Trends Cancer. 2017 Nov;3(11):753-760. doi: 10.1016/j.trecan.2017.09.001. Epub 2017 Oct 24. PMID: 29120751; PMCID: PMC5802368.

33. Palacios J., Matías-Guiu X., Rodríguez-Peralto J. L., Retos e implicaciones clínicas de la heterogeneidad intratumoral. Revista Española de Patología. 2019; 52(4):234-241. https://doi.org/10.1016/j.patol.2019.04.004

34. Soluciones diagnósticas para cáncer de mama. Entregando diagnósticos confiables. Ventana Medical Systems, Inc.   2017.

35. López García,. Características histopatológicas e inmunohistoquímicas de los carcinomas de mama diagnosticados en programas de cribado de cáncer de mama. Sevilla. 2018.  https://www.juntadeandalucia.es/salud/portaldeetica/xhtml/ayuda/verificarFirmaDocumento.iface/code/cf241064284d6c5ec6a605aed5ce489a4cdc5bcd

36. Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol 2020; 38: 444–53.

37. Asif HM, Sultana S, Ahmed S, Akhtar N, Tariq M. HER-2 Positive Breast Cancer - a Mini-Review. AsianPac J Cancer Prev. 2016; 17(4):1609-15. doi: 10.7314/apjcp.2016.17.4.1609. PMID: 27221828.

38. Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724. PMID: 27137076.

39. Priyanka Sharma MD. Major Strides in HER2 Blockade for Metastatic Breast Cancer. N Eng J Med. 2020, 382(7):669-671.

40. Murthy RK, Loi S, Okines A, Paplomata E, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Eng J Med. 2019

41. Giuliano AE, Connolly JL, Edgy S. Breast Cancer- Major Changes in the American Joint Committee on Cancer Eigth Edition Cancer Staging Manual. Ca Cancer J Clin 2017. 67 290-303

42. Testa U, Castelli G, Pelosi E. Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med. Sci. 2020, 8, 18; doi:10.3390/medsci8010018 

43. Schmid P, Adams S, Rugo HS. Atezolizumab and Nab-paclitaxel in advanced triple negative breast cancer. N Engl J Med. 2018; 379:2108-2121.

44. Medina Bueno GA. Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica. Arequipa, Perú. Rev. Perú Med Exp Salud Pública [Internet]. 2017 Jul-Set [citado 19 octubre 2020]; 34(3): 472-477. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342017000300014  

45. Cejalvo JM, Martínez de Dueñas E, Galván P, et. Al. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1. PMID: 28249905; PMCID: PMC5822682.

46. Socorro Castro C, Quiñones Ceballos AB. La inmunohistoquímica ¿una herramienta milagrosa? Medisur. 2017, 15(6):763

47. Mueller C, Haymond A, Davis JB, Williams A, Espina V. Protein biomarkers for subtyping breast cancer and implications for future research. Expert Rev Proteomics. 2018 Feb;15(2):131-152. doi: 10.1080/14789450.2018.1421071. Epub 2018 Jan 3. PMID: 29271260; PMCID: PMC6104835.

48. Bertucci F, Ng CKY, Patsouris A. Genomic characterization of metastatic breast cancers. Nature. 2019; 569:560-564.

49. DeVita, Hellman, and Rosenberg’s Cancer. Principles & Practice of Oncology. 2019. 11th edition. WoltersKluwer.

50. Luciano Stóver AC, Montejo Viamontes N, Loys Fernández JL, Vila García E. Resultados del tratamiento quirúrgico del cáncer de mama en mujeres hasta 40 años de edad. Rev Cubana Cir  [Internet]. 2018 Jun [citado 19 octubre 2020];  57(2): [aprox. 10p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003474932018000200006&lng=es

51. Romero Pérez T, Abreu Ruiz G, Monzón Fernández AN, Bermejo Bencomo W. Programa Integral para el control del cáncer en Cuba. Cáncer de mama: guía de práctica clínica en diagnóstico y tratamiento. La Habana, 2013. ISBN 978-959-212-817-0

52. Iannessi A, Beaumont H, Liu Y, Bertrand AS. RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline? Insights Imaging. 2021 Mar 18;12(1):36. doi: 10.1186/s13244-021-00976-w. PMID: 33738548; PMCID: PMC7973344.

53. Furrukh M, Qureshi A. Treatment Of Breast Cancer; Review And Updates. J Ayub Med Coll Abbottabad. 2018 Apr-Jun;30(2):264-274. PMID: 29938432.

54. Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. doi: 10.1038/nrclinonc.2016.195. Epub 2016 Dec 20. PMID: 27995946.

55. Soriano García JL y Col. Manual de Cáncer de mama. La Habana. 2017

56. Poveda Miranda, J. S. Perfil inmunohistoquímico en mujeres con cáncer de mama atendidas en el Hospital Bertha Calderón Roque en el período de Enero 2016- Enero 2017. (internet). Universidad nacional autónoma de Nicaragua unan- Managua; 2017 (citado 19 octubre de 2020). Disponible en: http://repositorio.umam.edu.ni/4374/1/96863.pdf

57. Maffus-Aziz A, Labastida- Almendaro S, Espejo- Fonseca A, Rodruíguez- Cuevas S. Clinical and payhological features of breast cancer in a population of Mexico. Cirugía y Cirujanos. (Internet). May- June 2017 (citado 19 octubre 2020); 85 (3): aprox. 6p. Disponible en: http://www.sciencedirect.com/science/article/pii/S000974111630069X

58. American Cancer Society. Breast Cancer Fact& Figures 2019- 2020. Atlanta: American Cancer Society, Inc. 2019.

59. Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/ HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res Treat. 2017;165(3):743-750.

60. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 Jan 19;354(3):270-82. doi: 10.1056/NEJMra050776. PMID: 16421368.

61. Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol (Lausanne). 2021 Mar 25; 12:599586. doi: 10.3389/fendo.2021.599586. Erratum in: Front Endocrinol (Lausanne). 2021 May 11;12:689705. PMID: 33841325; PMCID: PMC8030661.

62. Harold J. Burstein, M.D. Systemic Therapy for Estrogen Receptor– Positive, HER2-Negative Breast Cancer. N Engl J Med 2020; 383:2557-70. 

63. González- Müler C. Características patológicas asociadas al carcinoma de mama Her-2 positivo. An. Fac. med (Internet). 2005 Jun (citado 19 octubre 2020); 66(2): 89-99. Disponible en: http://www.scielo.org.pe/scielo.php?script=aci_arttext&pid=S1025-55832005000200002&Ing=es  

64. Esparza Ortega, M.A; Tapia Calvopiña, M.P. Determinación de marcadores tumorales por Inmunohistoquímica en muestras histopatológicas de pacientes con diagnóstico de Cáncer de Mama durante el periodo 2014-2017 en el Hospital San Francisco de Quito. Ecuador, 2019.

65. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;28:28.

 

 

 

 

 

 

BIBLIOGRAFÍA CONSULTADA

  • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Annals of Oncology, 2018; 29(8):1634–1657
  • Albanell J, Svedman C, Gligorov J. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Eur J Cancer 2016; 66: 104-13.
  • Allison KH, Hammond MEH, Dowsett M, Estrogen and progesterone receptor testing in breast cancer: ASCO/ CAP guideline update. J Clin Oncol 2020; 38: 1346-66.
  • American Cancer Society. ¿Cómo se origina el cáncer de seno? [Internet]. 2018.(citado 19 octubre 2020). Disponible en: https://www.cancer.org/es/cancer/cancer-de-seno/acerca/como-se-forma-el-cancer-de-seno.html
  • Anders What’s the Price? Toxicities of Targeted Therapies in Breast Cancer. BREAST CANCER. 2020: 55-70. asco.org/edbook.
  • André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med 2019; 380: 1929-40.
  • Bachelot T, Ciruelos E, Schneeweiss A. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). AnnalsofOncology 2019(30): 766-773.
  • Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E. Optimal duration of extended adjuvant endocrine therapy for early breast cancer: results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst 2018; 110(1).
  • Blum JL, Flynn PJ, Yothers G, Anthracyclines in early breast cancer: the ABC trials — USOR 06-090, NSAPB B-46-I/ USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017; 35: 2647-55.
  • BorislavKondov, ZvonkoMilenkovikj, Goran Kondov, Gordana Petrushevska, NeliBasheska, Magdalena Bogdanovska-Todorovska, et. al. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients; Open Access Maced J Med Sci. 2018 Jun 20; 6(6): 961–967.
  • Bouwer NI. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. TheBreast 2020; 52: 33-44.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre Lam, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. CA: A Cancer JournalforClinicians, 68: 394-424. doi: 10.3322 / caac.21492.
  • Buys SS, Sandbach JF, Gammon A, A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 2017; 123: 1721-30.
  • Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgués Gasion O, Paré L, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017, 77, 2213–2221.
  • Cortés J MD, Diéras V MD, Lorenzen S MD. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer A Phase 1 and Randomized Phase 2 Trial. JAMA Oncol.doi:10.1001/jamaoncol.2020.1796 Publishedon line June 25,2020.
  • Cottu P, D’Hondt V, Dureau S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of highrisk luminal breast cancer. Ann Oncol 2018; 29: 2334-40.
  • Desmedt C, Zoppoli G, Gundem G. Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol 2016; 34: 1872-81.
  • Dowsett M, Turner N. Estimating risk of recurrence for early breast cancer: integrating clinical and genomic risk. J Clin Oncol 2019; 37: 689-92.
  • Early Breast Cancer, ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2019
  • Edward Chu MD, Vincent T, DeVita Jr. MD. PHYSICIANS’ CANCER CHEMOTHERAPY DRUG MANUAL. 2020. ISSN: 1536-0008
  • ESMO Breast Cancer Essentials for Clinicians. 2017. ISBN: 978-88-941795-3-8
  • Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. SPECIAL ARTICLE. AnnalsofOncology 2019; 30(10):1541–1557.
  • Ethier JL, Ocana A, Rodríguez Lescure A, Ruiz A, Alba E, Calvo L, et al. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. Eur. J. Cancer 2018, 94, 199–205.
  • Farina A, Lima Ribeiro de Almeida L, Jesús de Paula LE, Vilela Medeiros R, Reginaldo Silva M, BarassuolSommavilla S. Perfil epidemiológico, clínico, anátomo patológico e imunohistoquímico das pacientes comcâncer de mama em Cuiabá (MT). RevBrasMastologia [Internet]. 2017; (citado 19 octubre 2020). 27(1):74-9. Disponible en: http://www.mastology.org/wp-content/uploads/2017/01/MAS-v27n1_74-79.pdf
  • Francis PA, Pagani O, Fleming GF, Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379: 122-37.
  • Hayes DF, Rae JM. Pharmacogenomics and endocrine therapy in breast cancer. J Clin Oncol 2020; 38: 525-8.
  • Im SA, Lu YS, Bardia A, Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019; 381: 307-16.
  • Iwata H, Masuda N, Yamamoto Y, Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat 2019; 173: 123-33.
  • Jambo Mendoza Juan TTK. Perfil inmunohistoquímico del carcinoma infiltrante de mama en menores y mayores de 40 años de edad. Hospital nacional “Almanzor Aguinaga Asenjo”. Chiclayo, 2014-2015. [Internet]. Universidad Pedro Ruiz Gallo; 2018 (citado 19 octubre 2020). Available from: http://repositorio.unprg.edu.pe/bitstream/handle/unprg/1818/bc-tes-tmp669.pdf?sequence=1&isAllowed=y
  • Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, et al. Predictors of chemosensitivity in triple negative breast cancer: An integrated genomic analysis. PLOS Med. 2016, 13, e1002193.
  • Kalinsky K, Barlow WE, Meric-Bernstam F, First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOGS1007 (RxPONDER). Presented at the virtual San Antonio Breast Cancer Symposium, December 8–11, 2020. abstract.
  • Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat. Rev Clin. Oncol. 2017, 14, 595–610.
  • Li Y, Yang D, Yin X, Clinicopathological characteristics and breast cáncer specific survival of patients with single hormone receptor-positive breast cancer. JAMA Netw Open 2020; 3(1): e1918160.
  • Liu XY, Ma D, Xu XE, Jin X, Yu KD, Jiang YZ et al. Genomic landscape and endocrine resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and HER2-negative breast cancer. Theranotics 2018, 8, 6386–6399.
  • VilagranFraguella M, Sentís Crivilléa M, del Riego Ferraria J, Andreu Navarrob FJ, Dalmau Portulàsc E, Planas Roquerolsd J, et al. Carcinoma de mama triple negativo. Heterogeneidad inmunofenotípica y en  el comportamiento farmacocinético. Radiología. 2016; 58(1):55-63.
  • Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase II study. J. Clin. Oncol. 2019.
  • Mamounas EP, Bandos H, Lembersky BC. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/ NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 88-99.
  • Nayar U, Cohen O, Kapstad C, Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019; 51: 207-16.
  • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH et al. Whole- genome sequencing reveals clinically relevant insights into the etiology of familial breast cancers. Ann. Oncol. 2019, 30, 1071–1079.
  • Noske A, Möbus V, Weber Kñ. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Eur J Cancer. 2019; 114: 76-88.
  • Pan H, Gray R, Braybrooke J. 20 Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017; 377: 1836-46.
  • Partridge AH, Hughes ME, Warner ET, Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016; 34: 3308-14.
  • Prado-Vazquez G, Gamez-Pozo A, Trilla-Fuertes L, Arevaliullo JM, Zapater-Moros A, Ferrer-Gomez M et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Sci. Rep. 2019, 9, 1538.
  • Ramírez Torres N, Rivas Ruiz R, García García JJ. Los subtipos moleculares en cáncer de mama avanzado  responden diferente a la quimioterapia neoadyuvante: evaluación de la respuesta patológica completa y pronóstico; Gac Mex Oncol. 2018; 17: 3-14.
  • Robson M, Im S-A, Senkus E. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377: 523-33.
  • Ruhstaller T, Giobbie-Hurder A, Colleoni M, Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019; 37: 105-14.
  • Sant M, Meneghini E, Bastos J. Endocrine treatment and incidence of relapse in women with oestrogen receptor‑positive breast cancer in Europe: a population‑based study. Breast Cancer Research and Treatment. 2020
  • Savard. Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. 2019: 8-20. asco.org/edbook.
  • Sestak I, Buus R, Cuzick J, Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018; 4: 545-53.
  • Sledge GW Jr, Toi M, Neven P, The effect of abemaciclib plus fulvestrant on overall survival in hormone-receptor positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2: a randomized trial. JAMA Oncol. 2019; 6: 116-25.
  • Sparano JA, Gray RJ, Ravdin PM. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019; 380: 2395-405.
  • Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020; 395: 817-27.
  • Tanya E, Keenan MD, MPH and Sara M. Tolaney, MD, MPH. Role of Immunotherapy in Triple-Negative Breast Cance. J Natl ComprCancNetw. 2020;18(4):479–489
  • Tolanev SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2019, 37, 1868–1875.
  • Tung NM, Boughey JC, Pierce LJ, Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020; 38: 2080-106
  • Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018; 119: 141-52.
  • Turner NC, Slamon DJ, Ro J, Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018; 379: 1926-36.
  • Ugo Testa *, Germana Castelli and Elvira Pelosi. Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med. Sci. 2020, 8, 18; doi:10.3390/medsci8010018
  • Untch M, von Minckiwitz G, Gerber B, Schem C, Rezai M, Fasching PA et al. Trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer in the GeparQuinto (G5) study (GBG 44). J Clin Oncol. 2018, 36, 1308– 1316.
  • Vallon-Christersson J, Hakkinen J, Hegardt C, Saal LH, Larsson C, Ehinger, A, et al. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Sci. Rep. 2019, 9, 12184.
  • Vithas Internacional. Avances diagnósticos y pronósticos en el cáncer de mama. [Internet]. 2018.(citado 19 octubre 2020). Disponible en: https://www.vithasinternacional.com/avances-en-el-cancer-de-mama/
  • Weiss A, King TA, Hunt KK, Mittendorf EA. Incorporating biologic factors into the American Joint Committee on Cancer Breast Cancer staging system: review of the supporting evidence. Surg Clin North Am. 2018; 98: 687-702.
  • Wu N, Fu F, Chen L, Lin Y, Yang P, Wang C. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: A systematic review and meta-analysis. Clin. Transl. Oncol. 2019.
  • Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, et al. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: Results of the WSG-PRIMe study. Breast Cancer Res. Treat. 2019, 175, 389–399.

 

 


Texto completo: Trabajo

Comentarios sobre el trabajo

  • Asunto: Interesante presentación

    Excelente investigacion felicitaciones 

    Especialista de 2do Cirugía General José Alberto Puerto Lorenzo , Hospital Provincial Dr. Gustavo AldereguÍa Lima. (2023-03-22)
  • Asunto: Impacto

    Quedó demostrado el beneficio en la implementación de la técnica de inmunohistoquímica en la provincia de Matanzas.

    Mis parabienes a los autores.

    Licenciada en Educación. Especialidad B Ilieth Acosta Nápoles , Hospital Municipal Armando E Cardoso. (2023-03-27)
Cierre de comentarios el día 2023-03-29.
Ver todos los comentarios